| Identification | Back Directory | [Name]
GNE-8505 | [CAS]
1620573-48-9 | [Synonyms]
GNE-8505
5-(1-(cyclopropylmethyl)-5-(3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1H-pyrazol-3-yl)-3-(trifluoromethyl)pyridin-2-amine | [Molecular Formula]
C21H24F3N5O | [MDL Number]
MFCD32062764 | [MOL File]
1620573-48-9.mol | [Molecular Weight]
419.44 |
| Chemical Properties | Back Directory | [Boiling point ]
552.3±50.0 °C(Predicted) | [density ]
1.69±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
8.30±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
GNE-8505 is a DLK inhibitor (IC50 = 10nM). | [Uses]
GNE-8505 is an orally available inhibitor of Dual leucine zipper kinase (DLK)[1]. | [References]
[1] Le Pichon CE, et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med. 2017 Aug 16;9(403). pii: eaag0394. DOI:10.1126/scitranslmed.aag0394 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|